Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by yoplaiton Jul 25, 2012 10:18am

182 Views

Post# 20150064

RE: RE: Options granted-who would of thought!!!!!!

So, management thinks with brute determination they can acheive a SP price increase from .145 to .16 in only 5 years? Talk about pulling a rabitt out of the old preverbial hat! They must be confident in their stellar management team to make such bold assertions...talk about a long shot to put those options "in the money".

I guess time will tell.

Good Luck to them and US.

Bullboard Posts

Abcourt Mines launches Flordin property drill campaign